There are currently 1304 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750
Recruiting
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Prurigo Nodularis
Register for Updates
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Grady Health System, Atlanta, Georgia +4 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Grady Health System, Atlanta, Georgia +3 locations
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Register for Updates
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
03/28/2025
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Parkinson Disease
Register for Updates
Effect of Cognitive Empathy Training on Dementia Caregivers
NCT06650527
Recruiting
The goal of this project is to investigate the effect of cognitive empathy training on mental health, inflammation, and immune function in caregivers of people living with dementia (PLWD), and to examine the underlying psychological and neurobiological mechanisms. The primary aim is to establish the effectiveness of cognitive empathy training in improving caregiver mental health and immune function, and in decreasing caregiver inflammation The secondary aim is to investigate the psychological... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/28/2025
Locations: Alter, Atlanta, Georgia +2 locations
Conditions: Caregivers of People Living with Dementia, Dementia
Register for Updates
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
NCT04803201
Recruiting
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Grady Health System, Atlanta, Georgia +3 locations
Conditions: Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Register for Updates
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Piedmont Healthcare, Atlanta, Georgia
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227
Recruiting
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
03/28/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Eosinophilic Esophagitis
Register for Updates
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696
Recruiting
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/28/2025
Locations: Piedmont West, Atlanta, Georgia
Conditions: Systemic Lupus Erythematosus
Register for Updates
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
NCT05677100
Recruiting
Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/28/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
Register for Updates
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
NCT06414603
Recruiting
This is an open label Comparative Effectiveness Research (CER) study in which patients will be randomized at the site level to Prospera surveillance or EMB surveillance in a 2:1 ratio (Prospera to EMB) at each site. Subjects will be enrolled into the study while under evaluation for heart transplantation or on the transplant waiting list prior to heart transplantation. All subjects will follow the center's standard of care surveillance schedule from transplant through 4 weeks post-transplantati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Piedmont Healthcare, Atlanta, Georgia
Conditions: Heart Transplant Failure and Rejection
Register for Updates
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085
Recruiting
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Gender:
ALL
Ages:
Between 29 days and 17 years
Trial Updated:
03/28/2025
Locations: Children's Healthcare of Atlanta - Arthur M. Blank Hospital ( Site 0001), Atlanta, Georgia
Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Register for Updates